PETALING JAYA: TMC Life Sciences Bhd’s net profit surged nearly fivefold to RM17.38 million for the financial year ended June 30, 2026 (FY26), from RM3.61 million a year earlier, driven by higher revenue and continued cost optimisation initiatives.
Revenue for the year rose 13.7% to RM393.03 million from RM345.54 million previously, while profit before tax climbed to RM25.74 million from RM7.07 million, according to a filing with Bursa Malaysia.
For the fourth quarter (Q4’26), net profit jumped 91.8% to RM4.65 million from RM2.42 million in the corresponding quarter last year, as revenue increased 6.5% to RM99.35 million from RM93.27 million.
The group said the stronger quarterly performance was underpinned by higher revenue and improved cost efficiency. Compared with the preceding quarter, revenue rose 11% while profit before tax surged 158% to RM7.08 million.
TMC said its earnings are supported by the recruitment of healthcare professionals, additional bed capacity and services, higher case intensity, as well as marketing efforts to strengthen its local and international branding.
Looking ahead, the healthcare group said it is pursuing a value-based care strategy as insurers and corporate customers place greater emphasis on affordability and value-based outcomes. It is also diversifying its revenue base through the corporate segment, a broader international patient mix and growing regional demand for fertility treatment.
The group also proposed a first and final single-tier dividend of 0.5763 sen per share for FY26, amounting to RM10.04 million, subject to shareholders’ approval, compared with 0.1863 sen per share, or RM3.25 million, for FY25.
